NCT07731490 Early Detection and IntervenTion in Heart Failure
| NCT ID | NCT07731490 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Heart Failure (HF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 18,000 participants |
| Start Date | 2025-12-03 |
| Primary Completion | 2028-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 18,000 participants in total. It began in 2025-12-03 with a primary completion date of 2028-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Heart failure (HF) occurs when the heart is no longer able to pump blood effectively throughout the body. This leads to symptoms that gradually worsen over time and are often mistaken for normal signs of aging. Because of its insidious onset, early detection is challenging. Both patients and healthcare professionals are often insufficiently aware of the early signs and symptoms of HF, resulting in delayed diagnosis. Consequently, timely initiation of treatments that could slow disease progression, improve quality of life, and reduce hospitalizations is often missed. Although a simple blood test measuring NT-proBNP levels can facilitate the early diagnosis of HF, it is not routinely used in clinical practice. The aim of this study is to evaluate whether a combined strategy for the early diagnosis and treatment of HF can reduce hospitalizations. This strategy includes: 1. increasing awareness of HF among patients and physicians, 2. using NT-proBNP testing for the early detection of HF in high-risk patients, and 3. promptly initiating guideline-directed HF treatment when the diagnosis is confirmed. The researchers will assess whether this strategy effectively reduces hospitalizations due to acute heart failure over an 18-month follow-up period.
Eligibility Criteria
Inclusion Criteria: * General consent (GC) has not been rejected. * Age ≥ 65 years. * Elective percutaneous coronary intervention\* (PCI), pulmonary vein isolation\* (PVI), pacemaker implantation\* (PM, no cardiac resynchronisation), transcatheter aortic valve intervention\* (TAVI), major non-cardiac surgery\* or presenting with tachyarrhythmia to the emergency department (ED) (without a diagnosis of HF within 24h). * Exclusion criteria are assessed on day 1 after the procedure Exclusion Criteria: * Systolic blood pressure ≤ 95 mmHg * Estimated glomerular filtration rate (GFR) \<30 mL/min/1.73 m2. * Dementia documented in the medical history. * Metastatic cancer in the medical history. * Previously enrolled in this study. * Known HF. * Known allergies, hypersensitivity, or intolerance to SGLT2 Inhibitors / Loop Diuretics / MRA or is excipients. * Non-resident in the country of the recruiting site * Incapacity of the patient to make judgements * Patients not hospitalized overnight * Patients requiring intensive care unit (ICU) or intermediate care (IMC) stay beyond 11:00 a.m. on the first postoperative day or any post-interventional stroke unit stay until 8:00 a.m. on the first postoperative day. * Patients died prior to postinterventional day 1 (8:00 a.m.) * Severe aortic or mitral stenosis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07731490 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Heart Failure (HF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07731490 currently recruiting?
Yes, NCT07731490 is actively recruiting participants. Contact the research team at Christian.Mueller@usb.ch for enrollment information.
Where is the NCT07731490 trial being conducted?
This trial is being conducted at Vienna, Austria, Sofia, Bulgaria, Freiburg im Breisgau, Germany, Herne, Germany and 11 additional locations.
Who is sponsoring the NCT07731490 clinical trial?
NCT07731490 is sponsored by University Hospital, Basel, Switzerland. The trial plans to enroll 18,000 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.